SubHero Banner
Text

Enhertu®(fam-trastuzumab deruxtecan-nxki) – Expanded indication

May 5, 2022 - Daiichi Sankyo and AstraZeneca announced the FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki).

Download PDF